Barlow Wealth Partners Inc. Has $21.09 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Barlow Wealth Partners Inc. lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,710 shares of the pharmaceutical company’s stock after purchasing an additional 2,138 shares during the period. Vertex Pharmaceuticals comprises about 2.7% of Barlow Wealth Partners Inc.’s investment portfolio, making the stock its 10th largest position. Barlow Wealth Partners Inc.’s holdings in Vertex Pharmaceuticals were worth $21,090,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Simon Quick Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 1.1% during the fourth quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company’s stock worth $900,000 after acquiring an additional 24 shares during the period. Bourgeon Capital Management LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $546,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new position in Vertex Pharmaceuticals during the 4th quarter worth $1,007,000. Atomi Financial Group Inc. raised its position in Vertex Pharmaceuticals by 13.7% during the 4th quarter. Atomi Financial Group Inc. now owns 2,179 shares of the pharmaceutical company’s stock valued at $877,000 after purchasing an additional 262 shares in the last quarter. Finally, Transform Wealth LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.7% in the 4th quarter. Transform Wealth LLC now owns 24,900 shares of the pharmaceutical company’s stock worth $10,027,000 after buying an additional 891 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $427.89 on Wednesday. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company has a fifty day moving average of $439.34 and a 200 day moving average of $465.72.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.67 EPS. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Morgan Stanley raised their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Stifel Nicolaus upped their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. Finally, Scotiabank increased their target price on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the company a “sector perform” rating in a research report on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.